Open AccessBreast cancer molecular subtypes and survival in a hospital‐based sample in Puerto Rico
Author(s) -
Ortiz Ana Patricia,
Frías Orquidea,
Pérez Javier,
Cabanillas Fernando,
Martínez Lisa,
Sánchez Carola,
CapóRamos David E.,
GonzálezKeelan Carmen,
Mora Edna,
Suárez Erick
Publication year - 2013
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.78
Subject(s) - hazard ratio , medicine , breast cancer , proportional hazards model , oncology , confidence interval , estrogen receptor , progesterone receptor , epidemiology , hormone receptor , cancer , stage (stratigraphy) , gynecology , population , cancer registry , demography , biology , paleontology , environmental health , sociology
Information on the impact of hormone receptor status subtypes in breast cancer ( BC ) prognosis is still limited for Hispanics. We aimed to evaluate the association of BC molecular subtypes and other clinical factors with survival in a hospital‐based female population of BC cases in Puerto Rico. We analyzed 663 cases of invasive BC diagnosed between 2002 and 2005. Information on HER ‐2/neu ( HER ‐2) overexpression, estrogen ( ER ), and progesterone ( PR ) receptor status and clinical characteristics were retrieved from hospitals cancer registries and record review. Survival probabilities by covariates of interest were described using the Kaplan–Meier estimators. Cox proportional hazards models were employed to assess factors associated with risk of BC death. Overall, 17.3% of BC cases were triple‐negative ( TN ), 61.8% were Luminal‐A, 13.3% were Luminal‐B, and 7.5% were HER ‐2 overexpressed. In the multivariate Cox model, among patients with localized stage, women with TN BC had higher risk of death (adjusted hazard ratio [ HR ]: 2.57, 95% confidence interval [ CI ]: 1.29–5.12) as compared to those with Luminal‐A status, after adjusting for age at diagnosis. In addition, among women with regional/distant stage at diagnosis, those with TN BC ( HR : 5.48, 95% CI : 2.63–11.47) and those HER ‐2+, including HER ‐2 overexpressed and Luminal‐B, ( HR : 2.73, 95% CI :1.30–5.75) had a higher mortality. This is the most comprehensive epidemiological study to date on the impact of hormone receptor expression subtypes in BC survival in Puerto Rico. Consistent to results in other populations, the TN subtype and HER ‐2+ tumors were associated with decreased survival.